Clinical Trial Update: Satralizumab in Aneurysmal Subarachnoid Hemorrhage [EARLY_Phase 1]

View source ↗

Summary

The EARLY_PHASE1 trial of satralizumab for aneurysmal subarachnoid hemorrhage (with delayed cerebral ischemia) has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aneurysmal Subarachnoid Hemorrhage
• Delayed Cerebral Ischemia

Drugs mentioned

• Enspryng (satralizumab)

Snippet

Sponsor: University of Florida | Conditions: Aneurysmal Subarachnoid Hemorrhage, Delayed Cerebral Ischemia | EARLY_Phase 1 | Status: WITHDRAWN